Beginning on December 13th, Adjunct Associate Professor Raymond Chua Swee Boon will officially assume the position of the Health Sciences Authority ( HSA ).
On Thursday ( 12 September ), Adjunct Associate Professor Chua was appointed HSA’s CEO-designate.  ,
According to MOH and HSA in a combined press release on Thursday, he will take Dr. Mimi Choong May Ling’s place. She may retire from public service on December 1.
Adjunct Associate Professor Chua is currently the Deputy Director-General of Health ( Health Regulation ) at the Ministry of Health ( MOH). He is in charge of overseeing the laws governing medical services and information in Singapore in his role at MOH.
According to MOH and HSA, he may continue with this session in addition to his new position as CEO of HSA in order to “better synergise regulation operations and enforcement across care services, information and products.”
Alternative Associate Professor Chua has overseen a number of regulatory activities at MOH, including the Human Biomedical Research Act and the Healthcare Services Act’s passage and application.
According to the press release, these Acts improved the heath regulatory framework and introduced innovative forms of service delivery.
He also established regulation sandboxes for solutions such as healthcare, mobile inpatient care-at-home and medical genomic healthcare services.
Alternative Associate Professor Chua even played a vital role during the COVID-19 crisis, serving as Deputy Commander for the Medical Operations Taskforce and supporting COVID-19 medical procedures.
He serves as an adjunct associate professor at Duke University, the Saw Swee Hock School of Public Health, and the National University of Singapore ( NUS)’s Center for Regulatory Excellence.
Alternative Associate Professor Chua served as the Group Director of the Health Products Regulation Group at HSA prior to his appointment to the MOH.
MOH and HSA expressed gratitude to the retiring CEO, but MOH and HSA also noted that Dr. Choong was appointed as HSA’s deputy executive on July 1, 2014.
She has helped HSA achieve a number of notable accomplishments over the past ten years, raising its reputation and standing internationally in the regulation and technological fields, according to MOH and HSA.
Under her leadership, HSA became one of the primary three officials to achieve the World Health Organization’s Listed Authority standing in 2023 for its medicines regulatory system.
Globally, Dr Choong expanded and strengthened cooperation with drugs officials from Australia, Canada, Switzerland and the United Kingdom, accelerating Singapore’s exposure to novel and cost-effective treatments.
During the COVID-19 crisis, Dr Choong furthermore led HSA’s complete response efforts, which were essential to Singapore’s administration of the problems.
Dr. Choong was also responsible for the success of the National Blood Program, strengthening the relationship with the Singapore Red Cross to promote normal body donation, and ensuring an adequate and healthy blood supply in the wake of the 2016 Zika virus threat and the COVID-19 pandemic.